1.Biotherapy of cancer by anti-EGFR monoclonal antibody.
Jing WANG ; Zhi-Yun MENG ; Sou-Ting FU ; Gui-Fang DOU
Journal of Experimental Hematology 2007;15(5):1135-1138
Epidermal growth factor receptor (EGFR) is mutated, dysregulated or overexpressed in many epithelial malignancies, and EGFR activation has been found to be important in tumor growth and progression. Anti-EGFR monoclonal antibodies target the extracellular domain of EGFR; and show promising anti-tumor potential at clinical trials without severe side effects. In this article the pharmacokenetics and clinical study of 3 anti-EGFR monoclonal antibodies (cetuximab, panitumumab and nimotuzomab) were reviewed.
Antibodies, Monoclonal
;
pharmacokinetics
;
therapeutic use
;
Antibodies, Monoclonal, Humanized
;
Antineoplastic Agents
;
therapeutic use
;
Cetuximab
;
Humans
;
Neoplasms
;
therapy
;
Receptor, Epidermal Growth Factor
;
antagonists & inhibitors
;
immunology